FilingReader Intelligence

InnoCare Pharma revenue jumps 74% on drug sales

August 19, 2025 at 10:41 AM UTCBy FilingReader AI

InnoCare Pharma reported 74.3% revenue growth to RMB731.4 million for the six months ended June 30, up from RMB419.7 million previously. Growth was driven by Orelabrutinib sales rising 52.8% to RMB637.3 million.

The company's adjusted loss decreased significantly to RMB15,504 from RMB242,992 year-over-year. Key approvals included Orelabrutinib for first-line CLL/SLL treatment and Tafasitamab for relapsed DLBCL.

InnoCare maintains RMB7.7 billion cash to fund future development.

This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com

HKEX:9969Hong Kong Exchange

News Alerts

Get instant email alerts when InnoCare Pharma publishes news

Free account required • Unsubscribe anytime

Filing Activity Timeline

View Complete Filing History →